Triple-negative breast cancer.

By Debra L Winkeljohn. Clinical Journal of Oncology Nursing, 2008

2,840 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/3ba1a25aedc3e95be79c4d22c79020e7567e1490

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. N. Almansour
2. Lisa A. Carey
3. O. Farokhzad
4. N. Bertrand
5. Charles M. Perou
6. Xiaoyang Xu

In Oncology

1. N. Almansour
2. O. Farokhzad
3. Charles M. Perou
4. C. Hudis
5. S. Tolaney

In Pulmonary and Respiratory Medicine

1. N. Almansour

Citations in the corpus

• ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. (2021, background): “According to this definition, they represent ~15%-20% of all BCs.(68) Further details of TNBC definitions can be found in the supplementary text – section 2, available at Annals of Oncology online.”
• Awareness and current knowledge of breast cancer (2017, background): “This type is mainly destructive, commonly observed in premenopausal females, and is responsible for 10–15% of cases in white females, with a elevated occurrence [57].”
• Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence (2022, result): “The TNBC proportion in all age groups followed a similar trend (Hudis and Gianni, 2011; Khan et al., 2017).”
• Interactions of nanomaterials and biological systems: implications to personalized nanomedicine (2012, background): “EGFR is expressed at high levels in at least 20% of breast cancers overall, but in 60-70% of patients with TNBC [84], which makes EGFR a potential treatment target.”
• Triple-negative breast cancer--current status and future directions. (2009, background): “Growth factors such as EGFR, c-kit, or p53 mutation status and several proliferative mechanisms like mitogen-activated protein kinase (MAPK) and protein kinase components of the extracellular signal-regulated kinases (ERK) pathway have been indicated as possible determinants of sensitivity to chemot”
• Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). (2015, background): “TNBC is not a uniform entity.(23) By gene expression analysis, 70% to 80% of TNBCs display a basal-like profile, whereas the rest are a mix of other subtypes.”